JP2004536031A - 突出痛を治療するための方法および装置 - Google Patents
突出痛を治療するための方法および装置 Download PDFInfo
- Publication number
- JP2004536031A JP2004536031A JP2002549259A JP2002549259A JP2004536031A JP 2004536031 A JP2004536031 A JP 2004536031A JP 2002549259 A JP2002549259 A JP 2002549259A JP 2002549259 A JP2002549259 A JP 2002549259A JP 2004536031 A JP2004536031 A JP 2004536031A
- Authority
- JP
- Japan
- Prior art keywords
- analgesic
- patient
- drug
- systemic circulation
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 91
- 208000000003 Breakthrough pain Diseases 0.000 title claims description 111
- 230000000694 effects Effects 0.000 claims abstract description 112
- 238000010521 absorption reaction Methods 0.000 claims abstract description 82
- 230000001839 systemic circulation Effects 0.000 claims abstract description 61
- 229940079593 drug Drugs 0.000 claims abstract description 59
- 239000003814 drug Substances 0.000 claims abstract description 59
- 239000013583 drug formulation Substances 0.000 claims abstract description 20
- 230000000202 analgesic effect Effects 0.000 claims description 236
- 230000036407 pain Effects 0.000 claims description 136
- 208000002193 Pain Diseases 0.000 claims description 135
- 210000002966 serum Anatomy 0.000 claims description 79
- 230000002411 adverse Effects 0.000 claims description 57
- 210000001519 tissue Anatomy 0.000 claims description 44
- 238000009472 formulation Methods 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 39
- 230000007423 decrease Effects 0.000 claims description 15
- 229960002428 fentanyl Drugs 0.000 claims description 13
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 12
- 230000002035 prolonged effect Effects 0.000 claims description 12
- 230000004044 response Effects 0.000 claims description 12
- 230000009286 beneficial effect Effects 0.000 claims description 9
- 230000003111 delayed effect Effects 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 8
- 239000007922 nasal spray Substances 0.000 claims description 8
- 239000007937 lozenge Substances 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 229960005181 morphine Drugs 0.000 claims description 6
- 229940097496 nasal spray Drugs 0.000 claims description 6
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims description 5
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 5
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims description 5
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims description 5
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 5
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 claims description 5
- 229960001391 alfentanil Drugs 0.000 claims description 5
- 229960001736 buprenorphine Drugs 0.000 claims description 5
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims description 5
- 229960002069 diamorphine Drugs 0.000 claims description 5
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims description 5
- 229960001410 hydromorphone Drugs 0.000 claims description 5
- 229960003406 levorphanol Drugs 0.000 claims description 5
- 229960001797 methadone Drugs 0.000 claims description 5
- 210000002850 nasal mucosa Anatomy 0.000 claims description 5
- 229960002085 oxycodone Drugs 0.000 claims description 5
- 230000037361 pathway Effects 0.000 claims description 5
- 229960003394 remifentanil Drugs 0.000 claims description 5
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims description 5
- 229960004739 sufentanil Drugs 0.000 claims description 5
- 206010061533 Myotonia Diseases 0.000 claims description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
- 210000002200 mouth mucosa Anatomy 0.000 claims description 4
- 239000000668 oral spray Substances 0.000 claims description 4
- 229940041678 oral spray Drugs 0.000 claims description 4
- 230000008447 perception Effects 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 206010039897 Sedation Diseases 0.000 claims description 3
- 230000036280 sedation Effects 0.000 claims description 3
- 206010010774 Constipation Diseases 0.000 claims description 2
- 206010028813 Nausea Diseases 0.000 claims description 2
- 230000036592 analgesia Effects 0.000 claims description 2
- 208000002173 dizziness Diseases 0.000 claims description 2
- 230000008693 nausea Effects 0.000 claims description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 8
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims 1
- 206010038678 Respiratory depression Diseases 0.000 claims 1
- 208000032140 Sleepiness Diseases 0.000 claims 1
- 206010041349 Somnolence Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 230000001766 physiological effect Effects 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 description 60
- 239000000730 antalgic agent Substances 0.000 description 60
- 230000002085 persistent effect Effects 0.000 description 12
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 8
- 210000003169 central nervous system Anatomy 0.000 description 8
- 230000003278 mimic effect Effects 0.000 description 7
- 208000000094 Chronic Pain Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 210000000278 spinal cord Anatomy 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000002716 delivery method Methods 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000000929 nociceptor Anatomy 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 0 CCCCCCCCCI1SCCOC1CC(CC)[C@@](C)CCC[C@@](*)C=CC Chemical compound CCCCCCCCCI1SCCOC1CC(CC)[C@@](C)CCC[C@@](*)C=CC 0.000 description 1
- 206010012186 Delayed delivery Diseases 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033296 Overdoses Diseases 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003364 biologic glue Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000006397 emotional response Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229960004207 fentanyl citrate Drugs 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940124583 pain medication Drugs 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25462700P | 2000-12-11 | 2000-12-11 | |
| US10/013,266 US20020106407A1 (en) | 2000-12-11 | 2001-12-10 | Method and apparatus for treating breakthrough pain |
| PCT/US2001/048584 WO2002047688A2 (fr) | 2000-12-11 | 2001-12-11 | Procede et appareil pour traiter une douleur qui revient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2004536031A true JP2004536031A (ja) | 2004-12-02 |
Family
ID=26684628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002549259A Pending JP2004536031A (ja) | 2000-12-11 | 2001-12-11 | 突出痛を治療するための方法および装置 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20020106407A1 (fr) |
| EP (1) | EP1368033A2 (fr) |
| JP (1) | JP2004536031A (fr) |
| AU (1) | AU2002232606A1 (fr) |
| CA (1) | CA2431287A1 (fr) |
| MX (1) | MXPA03005189A (fr) |
| WO (1) | WO2002047688A2 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010501308A (ja) * | 2006-08-29 | 2010-01-21 | ユーロ−セルティーク エス．エイ． | 無針薬物送達デバイスにおけるオピオイド製剤の使用 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE388705T1 (de) | 2000-07-31 | 2008-03-15 | Nycomed Danmark Aps | Fentanyl zusammensetzung zur nasalen anwendung |
| DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
| NZ541167A (en) * | 2003-01-31 | 2008-07-31 | Orexo Ab | A rapid-acting pharmaceutical composition comprising e.g. fentanyl and particles insoluble in water |
| US20040253307A1 (en) * | 2003-02-04 | 2004-12-16 | Brian Hague | Sugar-free oral transmucosal solid dosage forms and uses thereof |
| BRPI0412924A (pt) * | 2003-07-25 | 2006-09-26 | Euro Celtique Sa | tratamento pré-operatório de dor pós-operatória |
| US20050065175A1 (en) * | 2003-09-24 | 2005-03-24 | Xanodyne Pharmacal, Inc. | Oral transmucosal methadone |
| US9662274B2 (en) * | 2014-04-11 | 2017-05-30 | Innovative Products, Inc. | Method of orally administering a treating agent over an extended period |
| US9650338B1 (en) | 2016-07-29 | 2017-05-16 | VDM Biochemicals, Inc. | Opioid antagonist compounds and methods of making and using |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5855908A (en) * | 1984-05-01 | 1999-01-05 | University Of Utah Research Foundation | Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient |
| US5288498A (en) * | 1985-05-01 | 1994-02-22 | University Of Utah Research Foundation | Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments |
| US4863737A (en) * | 1985-05-01 | 1989-09-05 | University Of Utah | Compositions and methods of manufacture of compressed powder medicaments |
| US4671953A (en) * | 1985-05-01 | 1987-06-09 | University Of Utah Research Foundation | Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics |
| US5122127A (en) * | 1985-05-01 | 1992-06-16 | University Of Utah | Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues |
| US4885173A (en) * | 1985-05-01 | 1989-12-05 | University Of Utah | Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities |
| US5132114A (en) * | 1985-05-01 | 1992-07-21 | University Of Utah Research Foundation | Compositions and methods of manufacture of compressed powder medicaments |
| US5785989A (en) * | 1985-05-01 | 1998-07-28 | University Utah Research Foundation | Compositions and methods of manufacturing of oral dissolvable medicaments |
| US5783207A (en) * | 1985-05-01 | 1998-07-21 | University Of Utah Research Foundation | Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine |
| US5288497A (en) * | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
| US5824334A (en) * | 1989-09-05 | 1998-10-20 | University Of Utah Research Foundation | Tobacco substitute |
| US5543434A (en) * | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| EP0759744B1 (fr) * | 1994-05-13 | 2001-10-17 | Aradigm Corporation | Formulation en aerosol contenant un narcotique |
| US20020006438A1 (en) * | 1998-09-25 | 2002-01-17 | Benjamin Oshlack | Sustained release hydromorphone formulations exhibiting bimodal characteristics |
| US6245347B1 (en) * | 1995-07-28 | 2001-06-12 | Zars, Inc. | Methods and apparatus for improved administration of pharmaceutically active compounds |
| US5658583A (en) * | 1995-07-28 | 1997-08-19 | Zhang; Jie | Apparatus and methods for improved noninvasive dermal administration of pharmaceuticals |
| US6284266B1 (en) * | 1995-07-28 | 2001-09-04 | Zars, Inc. | Methods and apparatus for improved administration of fentanyl and sufentanil |
| US5968547A (en) * | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| SE9803240D0 (sv) * | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
| GB9904911D0 (en) * | 1999-03-03 | 1999-04-28 | Scherer Ltd R P | Pharmaceutical compositions |
| US6319510B1 (en) * | 1999-04-20 | 2001-11-20 | Alayne Yates | Gum pad for delivery of medication to mucosal tissues |
| WO2000076477A1 (fr) * | 1999-06-16 | 2000-12-21 | Nastech Pharmaceutical Co., Inc. | Methodes et compositions permettant de traiter la douleur incidente |
| US6261595B1 (en) * | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
| ATE388705T1 (de) * | 2000-07-31 | 2008-03-15 | Nycomed Danmark Aps | Fentanyl zusammensetzung zur nasalen anwendung |
-
2001
- 2001-12-10 US US10/013,266 patent/US20020106407A1/en not_active Abandoned
- 2001-12-11 WO PCT/US2001/048584 patent/WO2002047688A2/fr not_active Ceased
- 2001-12-11 JP JP2002549259A patent/JP2004536031A/ja active Pending
- 2001-12-11 MX MXPA03005189A patent/MXPA03005189A/es unknown
- 2001-12-11 CA CA002431287A patent/CA2431287A1/fr not_active Abandoned
- 2001-12-11 EP EP01992134A patent/EP1368033A2/fr not_active Withdrawn
- 2001-12-11 AU AU2002232606A patent/AU2002232606A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010501308A (ja) * | 2006-08-29 | 2010-01-21 | ユーロ−セルティーク エス．エイ． | 無針薬物送達デバイスにおけるオピオイド製剤の使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002047688A3 (fr) | 2003-03-20 |
| US20020106407A1 (en) | 2002-08-08 |
| CA2431287A1 (fr) | 2002-06-20 |
| EP1368033A2 (fr) | 2003-12-10 |
| WO2002047688A2 (fr) | 2002-06-20 |
| AU2002232606A1 (en) | 2002-06-24 |
| MXPA03005189A (es) | 2004-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6893654B2 (en) | Two-stage transmucosal medicine delivery system for symptom relief | |
| US20090048237A1 (en) | Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms | |
| US20110091544A1 (en) | Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting | |
| US20100030187A1 (en) | Apparatus and Method for Controlling Headaches | |
| JPH10500664A (ja) | 痛みの管理及び解毒のための鼻腔及び眼球へのケタミン投与 | |
| JP2009506076A (ja) | 三叉神経疼痛のための薬物送達のための治療手順 | |
| EA006384B1 (ru) | Композиция фентанила для интраназального введения | |
| JP2011526889A (ja) | 局所局部的神経作用療法 | |
| Slappendel et al. | Itching after intrathecal morphine. Incidence and treatment | |
| TW200836738A (en) | Improvements in or relating to medicinal compositions | |
| US8987290B2 (en) | Use of opioid formulations in needle-less drug delivery devices | |
| JP6116246B2 (ja) | イオントフォレシスにより悪心および片頭痛を治療するための方法 | |
| Labafchi et al. | The Beneficial Effect of Preoperative Dexmedetomidine in Controlling Postoperative Pain, nausea, and vomiting after orthognathic surgery: a triple-blind Randomized Clinical Trial | |
| JP2004536031A (ja) | 突出痛を治療するための方法および装置 | |
| ZA200706640B (en) | Method for a treatment with a medicament combination and medicament combinations suitable for the same | |
| JP4173538B2 (ja) | 痛みの管理及び解毒のためのケタミンの点鼻及び点眼投与 | |
| Markley | Topical agents in the treatment of cluster headache | |
| KR20100022940A (ko) | 혈중 화학 물질을 제거하기 위한 방법 및 투약 요법 | |
| Cugini et al. | Sedation with ketamine during cataract surgery | |
| HUP0100599A2 (hu) | Lokális anesztetikumok új alkalmazása vaszkuláris fejfájások ellen | |
| Zimmer et al. | Noninvasive drug delivery | |
| Panahandeh et al. | Does Unidirectional Buccal Patches Loaded With Lidocaine and Dexmedetomidine Ameliorate Injection Pain in Dental Procedures? A Double‐Blinded Randomized Controlled Trial | |
| JP2005535645A (ja) | 治療を実行するための併用治療および手段 | |
| Limoge et al. | Improvement of postoperative analgesia during cancer surgery with Limoge's current: a personal experience | |
| Sadovsky | Pharmacologic Treatment to Help with Smoking Cessation |